相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Effect of a Widespread Cancer-Causing Mutation on the Inactive to Active Dynamics of the B-Raf Kinase
Kristen A. Marino et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)
Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation
Neroshan Thevakumaran et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)
Molecular mechanisms of asymmetric RAF dinner activation
Pablo G. Jambrina et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers
Jiancheng Hu et al.
CELL (2013)
It takes two to tango - signalling by dimeric Raf kinases
Angela Baljuls et al.
MOLECULAR BIOSYSTEMS (2013)
Deciphering the Structural Basis of Eukaryotic Protein Kinase Regulation
Hiruy S. Meharena et al.
PLOS BIOLOGY (2013)
Conformation-Specific Effects of Raf Kinase Inhibitors Miniperspective
Xiaolun Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Identification of a Novel Family of BRAFV600E Inhibitors
Jie Qjn et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Vemurafenib: the first drug approved for BRAF-mutant cancer
Gideon Bollag et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Evolution of the eukaryotic protein kinases as dynamic molecular switches
Susan S. Taylor et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2012)
Single Substitution within the RKTR Motif Impairs Kinase Activity but Promotes Dimerization of RAF Kinase
Angela Baljuls et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Protein kinases: evolution of dynamic regulatory proteins
Susan S. Taylor et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
A dimerization-dependent mechanism drives RAF catalytic activation
Thanashan Rajakulendran et al.
NATURE (2009)
Differences between Ca2+ and Mg2+ in DNA binding and release by the SfiI restriction endonuclease: implications for DNA looping
Stuart R. W. Bellamy et al.
NUCLEIC ACIDS RESEARCH (2009)
Characterization of Ser338 Phosphorylation for Raf-1 Activation
Mengwei Zang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Xuewu Zhang et al.
CELL (2006)
Regulation and role of Raf-1/B-Raf heterodimerization
LK Rushworth et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization
MJ Garnett et al.
MOLECULAR CELL (2005)
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF
V Emuss et al.
CANCER RESEARCH (2005)
Positive and negative regulation of Raf kinase activity and function by phosphorylation
H Chong et al.
EMBO JOURNAL (2001)
分享论文
